The Journal of the Korea Contents Association (한국콘텐츠학회논문지)

The Korea Contents Association (한국콘텐츠학회)
권호 표지
DOI QR코드

DOI QR Code

Cardiovascular Risk Factors in Diabetic Patients according Duration of Diabetes Mellitus: The Sixth Korea National Health and Nutrition Examination Survey

당뇨병 유병기간에 따른 당뇨병 환자의 심혈관 위험 인자: 국민건강영양조사 6기 자료 이용

  • 김희성 (단국대학교 의과대학 제일병원 진단검사의학과)
  • Received : 2018.11.07
  • Accepted : 2018.12.15
  • Published : 2018.12.28
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to provide information on the treatment and management of diabetic patients using all the available data of the Korea National Health and Nutrition Examination Survey (KNHANES, 2013-2015) on the serological and complication patterns of cardiovascular disease (CVD) according to the duration of diabetes mellitus (DM). KNHANES consists of health questionnaires, screenings, and nutrition surveys. The study subjects were 1,316 persons who were aged between 18 and 80 years and who answered the duration of DM. DM was classified as 0-5, 6-10, 11-15, 16-20, and over 20 years according to duration of DM. The longer the duration of DM, the older the BMI, the lower the smoker, the higher the HbA1c and the lower the glomerular filtration rate. Total cholesterol, LDL-C and triglyceride levels were low and HDL-C levels were similar. The proportion of patients receiving insulin and oral hypoglycemic agents increased. The longer the duration of DM, the worse blood glucose control and the increased risk of microvascular and macrovascular complications. To prevent these complications, intensive care and monitoring should be used to control the risk factors.

당뇨병 유병기간에 따른 심혈관 질환의 혈청학적, 합병증의 양상을 국민건강영양조사 6기(2013-2015)의 모든 가용 데이터를 사용하여 당뇨병 환자의 치료뿐 아니라 향후 관리에 대한 정보를 제공함에 목적을 두고 있다. 국민건강영양조사는 건강 설문, 검진, 영양조사로 이루어져 있으며, 18~80세 미만으로 나이를 제한하였고, 당뇨병 유병기간을 응답한 1,316명을 조사 대상으로 하였다. 당뇨병 유병기간에 따라 0-5, 6-10, 11-15, 16-20, 20년 이상으로 구분하였다. 당뇨병 유병기간이 길어질수록 나이는 많아지고, BMI는 낮고, 흡연자의 비율은 떨어지며, HbA1c는 상승하고 사구체 여과율은 낮아졌다. 총 콜레스테롤, LDL-C, 중성 지방 수치는 낮고, HDL-C 수치는 비슷하였다. 인슐린 및 경구용 항고혈당제제를 치료 받는 환자의 비율은 증가하였다. 당뇨병 기간이 길수록 혈당 조절이 악화되었고, 미세혈관 및 대혈관합병증의 위험도는 상승하였다. 이러한 합병증을 예방하기 위해 집중적인 치료와 모니터링으로 위험요인을 통제해야 할 것이다.

Keywords

CCTHCV_2018_v18n12_208_f0001.png 이미지

그림 1. 자료선택의 흐름도. 국민건강영양조사 6기

CCTHCV_2018_v18n12_208_f0002.png 이미지

그림 2. 당뇨병 유병기간에 따른 심혈관 위험 인자들의 빈도 특성(%)

표 1. 당뇨병 유병기간에 따른 심혈관 위험 인자 특성

CCTHCV_2018_v18n12_208_t0001.png 이미지

표 2. 당뇨병 유병기간에 따른 심혈관 위험인자들의 위험도

CCTHCV_2018_v18n12_208_t0002.png 이미지

표 3. 당뇨병 유병기간에 따른 합병증의 빈도특성

CCTHCV_2018_v18n12_208_t0003.png 이미지

References

  1. J. A. Beckman, M. A. Creager, and P. Libby, "Diabetes and atherosclerosis: epidemiology, pathophysiology, and management," JAMA, Vol.287, No.19, pp.2570-2581, 2002. https://doi.org/10.1001/jama.287.19.2570
  2. J. Y. Jeon, S. H. Ko, H. S. Kwon, N. H. Kim, J. H. Kim, C. S. Kim, K. H. Song, J. C. Won, S. Lim, S. H. Choi, M. J. Jang, Y. Kim, K. Oh, D. J. Kim, B. Y. Cha, and A. Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes, "Prevalence of Diabetes and Prediabetes according to Fasting Plasma Glucose and HbA1c," Diabetes Metab J, Vol.37, No.5, pp.349-357, 2013. https://doi.org/10.4093/dmj.2013.37.5.349
  3. C. A. Reasner, "Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors," J Cardiovasc Pharmacol, Vol.52, No.2, pp.136-144, 2008. https://doi.org/10.1097/FJC.0b013e31817ffe5a
  4. S. Rao Kondapally Seshasai, S. Kaptoge, A. Thompson, E. Di Angelantonio, P. Gao, N. Sarwar, P. H. Whincup, K. J. Mukamal, R. F. Gillum, I. Holme, I. Njolstad, A. Fletcher, P. Nilsson, S. Lewington, R. Collins, V. Gudnason, S. G. Thompson, N. Sattar, E. Selvin, F. B. Hu, J. Danesh, and C. Emerging Risk Factors, "Diabetes mellitus, fasting glucose, and risk of cause-specific death," N Engl J Med, Vol.364, No.9, pp.829-841, 2011. https://doi.org/10.1056/NEJMoa1008862
  5. C. Centers for Disease and Prevention, "Prevalence of self-reported cardiovascular disease among persons aged > or =35 years with diabetes-United States, 1997-2005," MMWR Morb Mortal Wkly Rep, Vol.56, No.43, pp.1129-1132, 2007.
  6. Korea National Health and Nutrition Examination Survey, https://knhanes.cdc.go.kr/knhanes/sub03/sub03_02_02.do
  7. A. American Diabetes, "Standards of medical care in diabetes-2015 abridged for primary care providers," Clin Diabetes, Vol.33, No.2, pp.97-111, 2015. https://doi.org/10.2337/diaclin.33.2.97
  8. P. A. James, S. Oparil, B. L. Carter, W. C. Cushman, C. Dennison-Himmelfarb, J. Handler, D. T. Lackland, M. L. LeFevre, T. D. MacKenzie, O. Ogedegbe, S. C. Smith Jr., L. P. Svetkey, S. J. Taler, R. R. Townsend, J. T. Wright Jr., A. S. Narva, and E. Ortiz, "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)," JAMA, Vol.311, No.5, pp.507-520, 2014. https://doi.org/10.1001/jama.2013.284427
  9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)," JAMA, Vol.285, No.19, pp.2486-2497, 2001. https://doi.org/10.1001/jama.285.19.2486
  10. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults, "Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary," Am J Clin Nutr, Vol.68, No.4, pp.899-917, 1998. https://doi.org/10.1093/ajcn/68.4.899
  11. E. J. Lamb, C. R. Tomson, P. J. Roderick, and B. Clinical Sciences Reviews Committee of the Association for Clinical, "Estimating kidney function in adults using formulae," Ann Clin Biochem, Vol.42, No.Pt 5, pp.321-345, 2005. https://doi.org/10.1258/0004563054889936
  12. Korean Statistical Information Service, http://www.kosis.kr/statHtml/statHtml.do?orgId=117&tblId=DT_11702_N102
  13. R. Lajara, R. Aguilar, U. Hehnke, H. J. Woerle, and M. von Eynatten, "Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials," Clin Ther, Vol.36, No.11, pp.1595-1605, 2014. https://doi.org/10.1016/j.clinthera.2014.07.020
  14. E. Szoke, M. Z. Shrayyef, S. Messing, H. J. Woerle, T. W. van Haeften, C. Meyer, A. Mitrakou, W. Pimenta, and J. E. Gerich, "Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance," Diabetes Care, Vol.31, No.3, pp.539-543, 2008. https://doi.org/10.2337/dc07-1443
  15. D. J. Margolis, O. Hoffstad, and B. L. Strom, "Association between serious ischemic cardiac outcomes and medications used to treat diabetes," Pharmacoepidemiol Drug Saf, Vol.17, No.8, pp.753-759, 2008. https://doi.org/10.1002/pds.1630
  16. J. M. Gamble, S. H. Simpson, D. T. Eurich, S. R. Majumdar, and J. A. Johnson, "Insulin use and increased risk of mortality in type 2 diabetes: a cohort study," Diabetes Obes Metab, Vol.12, No.1, pp.47-53, 2010. https://doi.org/10.1111/j.1463-1326.2009.01125.x
  17. V. Patney, A. Whaley-Connell, and G. Bakris, "Hypertension Management in Diabetic Kidney Disease," Diabetes Spectr, Vol.28, No.3, pp.175-180, 2015. https://doi.org/10.2337/diaspect.28.3.175
  18. A. J. Hahr and M. E. Molitch, "Management of diabetes mellitus in patients with chronic kidney disease," Clin Diabetes Endocrinol, Vol.1, p.2, 2015. https://doi.org/10.1186/s40842-015-0001-9
  19. D. Orozco-Beltran, V. F. Gil-Guillen, F. Quirce, J. Navarro-Perez, M. Pineda, A. Gomez-dela- Camara, S. Pita, J. Diez-Espino, J. Mateos, J. Merino, M. Serrano-Rios, and I. Collaborative Diabetes Study, "Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain," Int J Clin Pract, Vol.61, No.6, pp.909-915, 2007. https://doi.org/10.1111/j.1742-1241.2007.01367.x
  20. F. P. Schena and L. Gesualdo, "Pathogenetic mechanisms of diabetic nephropathy," Journal of the American Society of Nephrology, Vol.16, No.3, Suppl.1, pp.S30-S33, 2005. https://doi.org/10.1681/ASN.2004110970
  21. M. J. Fowler, "Microvascular and macrovascular complications of diabetes," Clinical diabetes, Vol.26, No.2, pp.77-82, 2008. https://doi.org/10.2337/diaclin.26.2.77
  22. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, R. R. Holman, and G. Ukpds, "Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)," Kidney Int, Vol.63, No.1, pp.225-232, 2003. https://doi.org/10.1046/j.1523-1755.2003.00712.x
  23. F. A. El-Atat, S. N. Stas, S. I. McFarlane, and J. R. Sowers, "The relationship between hyperinsulinemia, hypertension and progressive renal disease," Journal of the American Society of Nephrology, Vol.15, No.11, pp.2816-2827, 2004. https://doi.org/10.1097/01.ASN.0000133698.80390.37
  24. P. J. Boyle, "Diabetes mellitus and macrovascular disease: mechanisms and mediators," Am J Med, Vol.120, No.9, Suppl.2, pp.S12-17, 2007. https://doi.org/10.1016/j.amjmed.2007.07.003
  25. M. Sakamoto, "Type 2 Diabetes and Glycemic Variability: Various Parameters in Clinical Practice," J Clin Med Res, Vol.10, No.10, pp.737-742, 2018. https://doi.org/10.14740/jocmr3556w
  26. M. Brownlee, "Glycation products and the pathogenesis of diabetic complications," Diabetes Care, Vol.15, No.12, pp.1835-1843, 1992. https://doi.org/10.2337/diacare.15.12.1835
  27. L. E. Garcia-Perez, M. Alvarez, T. Dilla, V. Gil-Guillen, and D. Orozco-Beltran, "Adherence to therapies in patients with type 2 diabetes," Diabetes Ther, Vol.4, No.2, pp.175-194, 2013. https://doi.org/10.1007/s13300-013-0034-y
  28. R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, S. Lafont, C. Bergeonneau, B. Kassai, S. Erpeldinger, J. M. Wright, F. Gueyffier, and C. Cornu, "Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: metaanalysis of randomised controlled trials," BMJ, Vol.343, p.d4169, 2011. https://doi.org/10.1136/bmj.d4169
  29. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, P. D. Reaven, F. J. Zieve, J. Marks, S. N. Davis, R. Hayward, S. R. Warren, S. Goldman, M. McCarren, M. E. Vitek, W. G. Henderson, G. D. Huang, and V. Investigators, "Glucose control and vascular complications in veterans with type 2 diabetes," N Engl J Med, Vol.360, No.2, pp.129-139, 2009. https://doi.org/10.1056/NEJMoa0808431
  30. F. B. Hu, M. J. Stampfer, C. G. Solomon, S. Liu, W. C. Willett, F. E. Speizer, D. M. Nathan, and J. E. Manson, "The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up," Archives of internal medicine, Vol.161, No.14, pp.1717-1723, 2001. https://doi.org/10.1001/archinte.161.14.1717
  31. W. B. Kannel, "Lipids, diabetes, and coronary heart disease: insights from the Framingham Study," Am Heart J, Vol.110, No.5, pp.1100-1107, 1985. https://doi.org/10.1016/0002-8703(85)90224-8
  32. R. M. Krauss and P. W. Siri, "Dyslipidemia in type 2 diabetes," Med Clin North Am, Vol.88, No.4, pp.897-909, 2004. https://doi.org/10.1016/j.mcna.2004.04.004
  33. S. J. Hamilton and G. F. Watts. "Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment," Rev Diabet Stud, Vol.10, No.2-3, pp.133-156, 2013. https://doi.org/10.1900/RDS.2013.10.133
  34. S. Natarajan, Y. Liao, D. Sinha, G. Cao, D. L. McGee, and S. R. Lipsitz, "Sex differences in the effect of diabetes duration on coronary heart disease mortality," Arch Intern Med, Vol.165, No.4, pp.430-435, 2005. https://doi.org/10.1001/archinte.165.4.430
  35. S. G. Wannamethee, A. G. Shaper, P. H. Whincup, L. Lennon, and N. Sattar, "Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors," Arch Intern Med, Vol.171, No.5, pp.404-410, 2011. https://doi.org/10.1001/archinternmed.2011.2
  36. E. B. Schroeder, L. E. Chambless, D. Liao, R. J. Prineas, G. W. Evans, W. D. Rosamond, G. Heiss, and S. Atherosclerosis Risk in Communities, "Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study," Diabetes Care, Vol.28, No.3, pp.668-674, 2005. https://doi.org/10.2337/diacare.28.3.668
  37. A. Gottsater, A. R. Ahlgren, S. Taimour, and G. Sundkvist, "Decreased heart rate variability may predict the progression of carotid atherosclerosis in type 2 diabetes," Clin Auton Res, Vol.16, No.3, pp.228-234, 2006. https://doi.org/10.1007/s10286-006-0345-4